---
title: "Top uniQure Executive Makes Eye-Catching Move With Insider Stock Sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291356166.md"
description: "uniQure's Chief Medical Officer, Walid Abi-Saab, sold 1,434 shares worth $67,197 on June 30, 2026. This insider sale occurred as the stock surged following analyst upgrades driven by plans to file a Q3 biologics license application for AMT-130 in Huntington’s disease under an accelerated approval path. Barclays and Cantor Fitzgerald raised outlooks citing FDA receptiveness and high sales potential. Despite strong technical momentum and positive pipeline developments, TipRanks' AI Analyst rates QURE as Neutral due to weak financial performance and negative earnings."
datetime: "2026-07-01T02:05:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291356166.md)
  - [en](https://longbridge.com/en/news/291356166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291356166.md)
generator: "portal-rs"
---

# Top uniQure Executive Makes Eye-Catching Move With Insider Stock Sale

New insider activity at uniQure ( (QURE) ) has taken place on June 30, 2026.

uniQure’s Chief Medical Officer, Walid Abi-Saab, recently reduced his holdings in the company by selling 1,434 shares of uniQure stock in a transaction valued at $67,197, highlighting a notable insider move in the biotech firm’s executive ranks.

uniQure shares surged over the last 24 hours as multiple analysts sharply revised their outlooks after the company said it plans to file a Q3 biologics license application for AMT-130 in Huntington’s disease under an accelerated approval path. Barclays and Cantor Fitzgerald cited the FDA’s receptiveness to existing data, a higher perceived probability of success, and the multi‑billion‑dollar peak sales potential of Huntington’s as key reasons for raising long‑term expectations for the stock.

**Spark’s Take on QURE Stock**

According to Spark, TipRanks’ AI Analyst, QURE is a Neutral.

The score balances strong technical momentum and several positive, pipeline-advancing corporate developments against weak underlying financial performance marked by deep losses and significant cash burn. Valuation is constrained by negative earnings (negative P/E) and no dividend support, keeping the overall score in the low-60s despite the bullish trend and regulatory/pipeline catalysts.

To see Spark’s full report on QURE stock,  
 click here. 

**More about uniQure**

**YTD Price Performance:** 98.04%

**Average Trading Volume:** 2,171,046

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $2.97B

### Related Stocks

- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [Walid Abi-Saab Sells 30,000 Shares of uniQure (NASDAQ:QURE) Stock](https://longbridge.com/en/news/291590037.md)
- [A Look At uniQure (QURE) Valuation After Strong Recent Share Price Gains](https://longbridge.com/en/news/288346961.md)
- [Belite Bio to present Phase 3 DRAGON tinlarebant results in Stargardt disease at SOG congress](https://longbridge.com/en/news/296615069.md)
- [14:18 ETVascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins](https://longbridge.com/en/news/296388379.md)
- [Billionaire Ray Dalio says today's artificial intelligence (AI) market echoes 1929 and 2000. History says investors should watch valuations closely](https://longbridge.com/en/news/296141586.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**